Susana Banerjee

Susana Banerjee at Royal Marsden has contributed to gynecologic oncology clinical research, including trials combining PARP inhibitors with checkpoint immunotherapy. The DUO-O trial and other trials investigating IO-PARP combinations exploit the hypothesis that PARP inhibitor-induced DNA damage may increase tumor mutational burden and neoantigen expression, potentially enhancing checkpoint immunotherapy response — an area of active investigation across gynecologic and other cancers.